(2) PRESS RELEASE
Immunocore presents phase 3 data comparing tebentafusp with investigator s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma
First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor
(Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator s choice in first-line metastatic uveal melanoma (mUM) in the clinical trial plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2021.
Study Shows Tanning Bed Ban Would Reduce Skin Cancer Rates in Minors and Cut Healthcare Costs
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Dr Thomas Cannell, President and CEO of Sesen Bio, and Dr Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dr Thomas Cannell, President and CEO of Sesen Bio, and Dr Michael Jewett, FRCSC, FACS, to Particip
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Title:
Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells
Presenter: Marcus O. Butler (PI)
Presentations and posters will be available for registered attendees for on-demand viewing on the AACR website beginning on April 10
th 2021.
About Immunocore
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology ther